S&P 500   3,123.85 (-3.16%)
DOW   27,046.43 (-3.27%)
QQQ   215.20 (-2.80%)
AAPL   290.50 (-2.58%)
FB   196.58 (-2.06%)
MSFT   168.17 (-1.59%)
GOOGL   1,390.84 (-2.04%)
AMZN   1,960.86 (-2.41%)
CGC   19.49 (-3.99%)
NVDA   260.83 (-4.56%)
BABA   204.36 (-0.87%)
MU   51.65 (-6.11%)
GE   11.20 (-5.56%)
TSLA   794.08 (-4.76%)
AMD   47.19 (-3.93%)
T   37.40 (-1.71%)
ACB   1.50 (-3.24%)
F   7.23 (-4.49%)
NFLX   358.29 (-2.82%)
PRI   122.41 (-3.59%)
BAC   31.05 (-5.13%)
DIS   128.31 (-3.53%)
GILD   69.11 (-5.20%)
S&P 500   3,123.85 (-3.16%)
DOW   27,046.43 (-3.27%)
QQQ   215.20 (-2.80%)
AAPL   290.50 (-2.58%)
FB   196.58 (-2.06%)
MSFT   168.17 (-1.59%)
GOOGL   1,390.84 (-2.04%)
AMZN   1,960.86 (-2.41%)
CGC   19.49 (-3.99%)
NVDA   260.83 (-4.56%)
BABA   204.36 (-0.87%)
MU   51.65 (-6.11%)
GE   11.20 (-5.56%)
TSLA   794.08 (-4.76%)
AMD   47.19 (-3.93%)
T   37.40 (-1.71%)
ACB   1.50 (-3.24%)
F   7.23 (-4.49%)
NFLX   358.29 (-2.82%)
PRI   122.41 (-3.59%)
BAC   31.05 (-5.13%)
DIS   128.31 (-3.53%)
GILD   69.11 (-5.20%)
S&P 500   3,123.85 (-3.16%)
DOW   27,046.43 (-3.27%)
QQQ   215.20 (-2.80%)
AAPL   290.50 (-2.58%)
FB   196.58 (-2.06%)
MSFT   168.17 (-1.59%)
GOOGL   1,390.84 (-2.04%)
AMZN   1,960.86 (-2.41%)
CGC   19.49 (-3.99%)
NVDA   260.83 (-4.56%)
BABA   204.36 (-0.87%)
MU   51.65 (-6.11%)
GE   11.20 (-5.56%)
TSLA   794.08 (-4.76%)
AMD   47.19 (-3.93%)
T   37.40 (-1.71%)
ACB   1.50 (-3.24%)
F   7.23 (-4.49%)
NFLX   358.29 (-2.82%)
PRI   122.41 (-3.59%)
BAC   31.05 (-5.13%)
DIS   128.31 (-3.53%)
GILD   69.11 (-5.20%)
S&P 500   3,123.85 (-3.16%)
DOW   27,046.43 (-3.27%)
QQQ   215.20 (-2.80%)
AAPL   290.50 (-2.58%)
FB   196.58 (-2.06%)
MSFT   168.17 (-1.59%)
GOOGL   1,390.84 (-2.04%)
AMZN   1,960.86 (-2.41%)
CGC   19.49 (-3.99%)
NVDA   260.83 (-4.56%)
BABA   204.36 (-0.87%)
MU   51.65 (-6.11%)
GE   11.20 (-5.56%)
TSLA   794.08 (-4.76%)
AMD   47.19 (-3.93%)
T   37.40 (-1.71%)
ACB   1.50 (-3.24%)
F   7.23 (-4.49%)
NFLX   358.29 (-2.82%)
PRI   122.41 (-3.59%)
BAC   31.05 (-5.13%)
DIS   128.31 (-3.53%)
GILD   69.11 (-5.20%)
Log in

NYSE:BHC - Bausch Health Companies Stock Price, Forecast & News

$24.55
-1.45 (-5.58 %)
(As of 02/25/2020 02:33 PM ET)
Today's Range
$24.43
Now: $24.55
$26.37
50-Day Range
$26.00
MA: $28.28
$30.25
52-Week Range
$18.72
Now: $24.55
$31.97
Volume3.52 million shs
Average Volume3.58 million shs
Market Capitalization$8.66 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.02
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone514-744-6792

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.60 billion
Cash Flow$9.70 per share
Book Value$3.22 per share

Profitability

Net Income$-1,788,000,000.00

Miscellaneous

Employees21,100
Market Cap$8.66 billion
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive BHC News and Ratings via Email

Sign-up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.


Bausch Health Companies (NYSE:BHC) Frequently Asked Questions

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc (NYSE:BHC) released its quarterly earnings data on Wednesday, February, 19th. The company reported $1.12 EPS for the quarter, missing the consensus estimate of $1.15 by $0.03. The company earned $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Bausch Health Companies had a negative net margin of 20.79% and a positive return on equity of 68.06%. The company's quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.05 EPS. View Bausch Health Companies' Earnings History.

When is Bausch Health Companies' next earnings date?

Bausch Health Companies is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Bausch Health Companies.

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies updated its FY 2020 Pre-Market earnings guidance on Wednesday, February, 19th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $8.65-8.85 billion, compared to the consensus revenue estimate of $8.78 billion.

What price target have analysts set for BHC?

15 equities research analysts have issued 1 year price targets for Bausch Health Companies' shares. Their forecasts range from $18.00 to $60.00. On average, they anticipate Bausch Health Companies' share price to reach $34.75 in the next year. This suggests a possible upside of 41.5% from the stock's current price. View Analyst Price Targets for Bausch Health Companies.

What is the consensus analysts' recommendation for Bausch Health Companies?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 1 sell rating, 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bausch Health Companies.

What are Wall Street analysts saying about Bausch Health Companies stock?

Here are some recent quotes from research analysts about Bausch Health Companies stock:
  • 1. According to Zacks Investment Research, "Bausch’s Bausch + Lomb/International and Salix segments maintain momentum on the back of several established brands, such as Xifaxan, BioTrue ONEday and Bausch + Lomb ULTRA. Newer products, such as Lumify and Thermage FLX, continue to perform well too. The initial uptake of psoriasis lotion, Duobrii, has been encouraging as well. After a tumultuous period, the company started a rebuilding process. Bausch has narrowed its focus on seven products — Vyzulta, Siliq, Bryhali, Lumify, Duobrii, Relistor and SiHy Daily. These have now been launched and hence the company’s performance is expected to be strong. However, the dermatology market continues to be challenging. Shares have outperformed the industry in the year so far." (12/16/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We employ a cash EPS multiple-based approach. The cash EPS number is derived from our adjusted 12-month income, which employs a total 12-month adjusted (non-GAAP) income projection of roughly $1.6B, which we divide by approximately 357M shares outstanding to derive our 12-month cash EPS of $4.46 per share." (8/7/2019)
  • 3. Cantor Fitzgerald analysts commented, "We rate BHC as 12-month price target of $32. A greater appreciation for BHC’s solid execution and future growth prospects under the new management team should drive upwards earnings revisions in 2019+, multiple expansion, and BHC shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $32." (4/25/2019)

Has Bausch Health Companies been receiving favorable news coverage?

Media stories about BHC stock have trended very negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bausch Health Companies earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Bausch Health Companies.

Are investors shorting Bausch Health Companies?

Bausch Health Companies saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 18,100,000 shares, an increase of 20.5% from the December 31st total of 15,020,000 shares. Based on an average trading volume of 3,860,000 shares, the days-to-cover ratio is presently 4.7 days. Currently, 5.2% of the shares of the company are short sold. View Bausch Health Companies' Current Options Chain.

Who are some of Bausch Health Companies' key competitors?

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Constellation Software (CSU), Gilead Sciences (GILD), Intact Financial (IFC), Micron Technology (MU), Netflix (NFLX), Alibaba Group (BABA), Bank of America (BAC), Twitter (TWTR), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

Who are Bausch Health Companies' key executives?

Bausch Health Companies' management team includes the folowing people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 64)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 63)
  • Mr. Thomas J. Appio, Pres & Co-Head Bausch + Lomb/International (Age 57)
  • Mr. William D. Humphries, Pres of Ortho-Dermatologics (Age 53)
  • Mr. Osama A. Eldessouky, Sr. VP, Controller & Chief Accounting Officer (Age 47)

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FIL Ltd (7.65%), Renaissance Technologies LLC (3.54%), Connor Clark & Lunn Investment Management Ltd. (1.32%), Thrivent Financial for Lutherans (0.68%), FMR LLC (0.54%) and CIBC World Markets Inc. (0.54%). Company insiders that own Bausch Health Companies stock include Christina Ackermann, John Paulson, Joseph C Papa, Mark C Mckenna, Paul Herendeen, Schutter Richard U De, Thomas Appio and William D Humphries. View Institutional Ownership Trends for Bausch Health Companies.

Which institutional investors are selling Bausch Health Companies stock?

BHC stock was sold by a variety of institutional investors in the last quarter, including Connor Clark & Lunn Investment Management Ltd., Cannell Peter B & Co. Inc., Commerzbank Aktiengesellschaft FI, FIL Ltd, Man Group plc, Russell Investments Group Ltd., M.D. Sass Investors Services Inc. and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Bausch Health Companies company stock in the last year include Christina Ackermann and Mark C Mckenna. View Insider Buying and Selling for Bausch Health Companies.

Which institutional investors are buying Bausch Health Companies stock?

BHC stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Fiera Capital Corp, Capital World Investors, MUFG Securities EMEA plc, Lakewood Capital Management LP, Redwood Capital Management LLC and Cubist Systematic Strategies LLC. Company insiders that have bought Bausch Health Companies stock in the last two years include John Paulson, Joseph C Papa, Paul Herendeen, Schutter Richard U De, Thomas Appio and William D Humphries. View Insider Buying and Selling for Bausch Health Companies.

How do I buy shares of Bausch Health Companies?

Shares of BHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $24.55.

How big of a company is Bausch Health Companies?

Bausch Health Companies has a market capitalization of $8.66 billion and generates $8.60 billion in revenue each year. The company earns $-1,788,000,000.00 in net income (profit) each year or $4.43 on an earnings per share basis. Bausch Health Companies employs 21,100 workers across the globe.View Additional Information About Bausch Health Companies.

What is Bausch Health Companies' official website?

The official website for Bausch Health Companies is http://www.bauschhealth.com/.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company can be reached via phone at 514-744-6792 or via email at [email protected]


MarketBeat Community Rating for Bausch Health Companies (NYSE BHC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  296 (Vote Outperform)
Underperform Votes:  322 (Vote Underperform)
Total Votes:  618
MarketBeat's community ratings are surveys of what our community members think about Bausch Health Companies and other stocks. Vote "Outperform" if you believe BHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Featured Article: What is a Buy-Side Analyst?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel